Emergent BioSolutions stock rises on government contract modification

Published 08/07/2025, 21:52
© Reuters.

Investing.com -- Emergent BioSolutions Inc (NYSE:EBS) stock rose 6.3% after the company announced a contract modification to deliver additional doses of its smallpox vaccination complication treatment to the U.S. government.

The company secured the modification from the Administration for Strategic Preparedness and Response (ASPR), part of the U.S. Department of Health and Human Services. Under the agreement, Emergent will provide additional doses of CNJ-016® [Vaccinia Immune Globulin Intravenous (Human)] (VIGIV), which treats complications arising from smallpox vaccination.

This modification exercises an option from ASPR’s existing 10-year contract with Emergent (contract number 75A50119C00037) for the treatment, which is part of the U.S. government’s smallpox preparedness strategy.

"Securing this contract modification for VIGIV treatment underscores Emergent’s ongoing partnership with the U.S. government to support its overall smallpox preparedness strategy," said Paul Williams, senior vice president, head of products business, global government & public affairs at Emergent.

The company did not disclose the financial terms of the contract modification in its announcement. Emergent BioSolutions specializes in developing and manufacturing medical countermeasures for public health threats through its North American supply chain.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.